Gilead Sciences, Inc.(NASDAQ:GILD) has attracted significant interest from investors recently. Analysts at financial institutions such as
UBS,
Leerink Partners,
TD Cowen, and
Citgroup have raised their price targets for GILD due to a positive Pharma sector outlook. Gilead's recent successes, notably the
Phase 3 win with
Trodelvy in TNBC, have caused a significant shift in its investment narrative. This heightened interest has led to increased activity among asset management firms, as demonstrated by sales and purchases of the stock by notable insiders like CEO
Daniel O'Day, institutions such as
Lingohr Asset Management,
Truist Financial Corp, and many others.
GILEAD recently reached a new 12-month high following an analyst upgrade, further boosting investor confidence. Despite some insider selling, the overall prediction for
Gilead Sciences' stock price is bullish. The expected release of Gilead's Q4 & full 2025 financial results on February 10, 2026, will provide a clearer short-term forecast.
Gilead Sciences GILD News Analytics from Thu, 20 Nov 2025 08:00:00 GMT to Sat, 31 Jan 2026 22:05:49 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor -3
